Pulmospheres — tiny, three-dimensional spheres made of lung cells taken from patients — can predict how well a person with idiopathic pulmonary fibrosis (IPF) will respond to medications commonly used to treat the disease, according to a new study. Currently, “flat” cultures of lung cells are used to study possible effects of drug treatments…
3-D Lung Spheres Grown from Biopsy Tissue May Predict IPF Patient Response to Treatment
Personalized Care for Idiopathic Pulmonary Fibrosis
In this PeerView Press video, pulmonologist Dr. David J. Lederer discusses idiopathic pulmonary fibrosis (IPF), with a focus on personalized care through communications and innovative strategies. He is joined by primary care physician Dr. Steven J. Antonini and pulmonary fibrosis patient Robert Brynteson. Read about six lesser-known symptoms of…
European patients with idiopathic pulmonary fibrosis (IPF) have lengthy and costly hospital stays, mainly because of acute respiratory events, according to a new study. There is a lack of information about the frequency of acute events among IPF patients, as well as on the outcomes, causes of poor prognosis, and financial burden of…
7 Health Benefits of Vitamin D
Vitamin D is often called the “sunshine vitamin,” mostly because we get it naturally when the sun’s UV rays interact with our skin, which triggers the vitamin’s synthesis. The vitamin helps our body’s absorption of calcium to keep our bones strong and encourage healthy cells to grow. Last year, researchers demonstrated the protective effects of vitamin…
A case report illustrates the possibility of treating cancer patients who develop bleomycin-triggered lung disease with Esbriet (pirfenidone) — a drug approved for idiopathic pulmonary fibrosis (IPF) treatment. Researchers acknowledged that further studies are needed, but they said combining Esbriet and corticosteroid drugs could completely reverse lung disease and prevent…
Evotec and MaRS Innovation have teamed to launch Fibrocor Therapeutics, a pharmaceutical company that will be dedicated to developing treatments for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Fibrocor received $2.1 million in financing, including cash from MaRS Innovation, the commercialization arm for 15 academic institutions in Ontario, Canada.
Doctors are calling for studies to ascertain whether Ofev (nintedanib) should be used to treat idiopathic pulmonary fibrosis (IPF) patients who suffer from acute exacerbations. Find out more about Ofev (nintedanib) here. This stems from the recent successful treatment of an 84-year-old man, who after being diagnosed with an…
I am quite aware of what I can no longer do, and grieve these losses. I also have found that focusing on what I CAN DO encourages me, and gives me hope and purpose. My sister Kyle and yours truly. My…
5 Pulmonary Fibrosis Questions for Your Doctor
If you’ve recently been diagnosed with pulmonary fibrosis, there are probably loads of questions running through your mind. Here are some of the most important questions you should ask your doctor according to the American Lung Association. 1. “What is pulmonary fibrosis?” Pulmonary fibrosis (PF) literally means scarring of the lungs.
Many of you who have been following my column know that I was lucky enough to return to Australia this past fall for three weeks. “Lucky”… it is such a funny word, because while some may say I was lucky to get to travel across the world, others…
Your PF Community
Recent Posts
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
- The greatest gift I’ve received wasn’t under the Christmas tree December 16, 2025
- Reversing caregiver roles taught me about emotional presence December 16, 2025
- Our response to a PF diagnosis was achieving a ‘life beyond limits’ December 11, 2025
- New IPF treatment moves ahead after encouraging study results December 10, 2025
